ImmunityBio, Inc. (IBRX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $8.00, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4); Elevated risk factors.
ImmunityBio is a biotech commercializing ANKTIVA (nogapendekin alfa inbakicept) for BCG-unresponsive NMIBC, approved in the U.S., UK, Saudi Arabia, and EU. ANKTIVA generated ~$113M net revenue in 2025 (700% YoY growth) and is being evaluated across NSCLC, lymphoma, and other... Read more
Hold if already holding. Not a fresh buy at $8.00, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4); Elevated risk factors. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Mixed signals. Hold existing position. Score 6.1/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent Developments — ImmunityBio, Inc.
Latest news
- ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout - Seeking Alpha — Seeking Alpha positive
- ImmunityBio: One Approval Away From A Multi-Billion Dollar Breakout (NASDAQ:IBRX) - Seeking Alpha — Seeking Alpha positive
- IBRX Stock Jumps Overnight After Major FDA Review Win For Anktiva In Bladder Cancer - Stocktwits — Stocktwits positive
- IBRX stock in spotlight: ImmunityBio to unveil fresh Anktiva and BCG data next week - MSN — MSN positive
- IBRX stock climbs overnight: ImmunityBio declares 'all systems go' for Dunkirk Anktiva manufacturing push - MSN — MSN positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $8.00, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4); Elevated risk factors. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Mixed signals. Hold existing position. Target $13.17 (+64.6%), stop $7.22 (−10.8%), A.R:R 4.7:1. Score 6.1/10, moderate confidence.
Take-profit target: $13.17 (+69.7% upside). Target $13.17 (+64.6%), stop $7.22 (−10.8%), A.R:R 4.7:1. Stop-loss: $7.22.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.4); Elevated risk factors; Value-trap signals (3/5): Margin compression (op margin -157.9%), Material insider selling (4 sells, 0.04% of cap), Negative free cash flow.
ImmunityBio, Inc. trades at a P/E of N/A (forward 76.2). TrendMatrix value score: 6.3/10. Verdict: Hold.
11 analysts cover IBRX with a consensus score of 4.3/5. Average price target: $16.
What does ImmunityBio, Inc. do?ImmunityBio is a biotech commercializing ANKTIVA (nogapendekin alfa inbakicept) for BCG-unresponsive NMIBC, approved in...
ImmunityBio is a biotech commercializing ANKTIVA (nogapendekin alfa inbakicept) for BCG-unresponsive NMIBC, approved in the U.S., UK, Saudi Arabia, and EU. ANKTIVA generated ~$113M net revenue in 2025 (700% YoY growth) and is being evaluated across NSCLC, lymphoma, and other solid tumors.